Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.

@article{Schlingensiepen2008AntisenseTF,
  title={Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.},
  author={K. H. Schlingensiepen and Birgit Fischer-Blass and Susanne Schmaus and Schmid Ludwig},
  journal={Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer},
  year={2008},
  volume={177},
  pages={
          137-50
        }
}
Overexpression of the cytokine transforming growth factor-beta 2 (TGF-beta2) is a hallmark of various malignant tumors including pancreatic carcinoma, malignant glioma, metastasizing melanoma, and metastatic colorectal carcinoma. This is due to the pivotal role of TGF-beta2 as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. The antisense technology is an innovative technique offering a targeted approach for the treatment… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS, ESTIMATED 55% COVERAGE

65 Citations

051015'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 65 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…